Can Bundled Payment Model Improve Breast Cancer Outcomes?

Article

This Medical News Minute examines a recent study that compared two payment models, fee-for-service vs bundled payment, to see if there was any effect on breast cancer outcomes.

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Lazzara discusses a recent study that compared two payment models, fee-for-service vs bundled payment, to see if there was any effect on breast cancer outcomes.

Related Videos
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Alexander Spira, MD, PhD, FACP, an expert on lung cancer
A panel of 4 experts on lung cancer
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Related Content
Findings support the use of 18F-PSMA-1007 PET/CT in the preoperative workflow of intermediate- and high-risk prostate cancer.

18F-PSMA-1007 PET/CT Improves Staging Vs MRI in Prostate Cancer

May 3rd 2024
Article

Findings support the use of 18F-PSMA-1007 PET/CT in the preoperative workflow of intermediate- and high-risk prostate cancer.

Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.

Applying Novel Radiotherapy Technology for Brain Tumors and Other Cancers

April 29th 2024
Podcast

Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.

Data also highlight a favorable overall survival trend with the acalabrutinib regimen in the phase 3 ECHO trial.

Acalabrutinib Combo Yields PFS Improvement Vs SOC in Mantle Cell Lymphoma

May 3rd 2024
Article

Data also highlight a favorable overall survival trend with the acalabrutinib regimen in the phase 3 ECHO trial.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

T-DXd given at 2 dose levels continued to show anti-tumor activity in patients with HER2-overexpressing non–small cell lung cancer.

T-DXd Yields Consistent Results in HER2-Overexpressing NSCLC

May 2nd 2024
Article

T-DXd given at 2 dose levels continued to show anti-tumor activity in patients with HER2-overexpressing non–small cell lung cancer.

The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.

Pembrolizumab Combo Yields Significant OS in HER2+ Gastric/GEJ Cancer

May 2nd 2024
Article

The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.